Cost effectiveness of liposomal doxorubicin versus paclitaxel for the treatment of ddvanced AIDS-Related Kaposis Sarcoma

Update Item Information
Title Cost effectiveness of liposomal doxorubicin versus paclitaxel for the treatment of ddvanced AIDS-Related Kaposis Sarcoma
Publication Type thesis
School or College College of Pharmacy
Department Pharmacotherapy
Author Raimundo, Karina Pupio
Date 2011-12
Description Epidemic Kaposis Sarcoma (AIDS- KS) is a rare cancer that occurs frequently among patients infected with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS). AIDS-KS is one of the most common AIDS-defining malignancies. To address the cosmetic issue and comorbidities associated with KS, the Food and Drug Administration (FDA) approved liposomal doxorubicin, liposomal daunorubicin and paclitaxel. The aim of this study is to compare liposomal doxorubicin (first-line treatment of AIDS KS) to paclitaxel (second-line) through a cost e↵ectiveness analysis and test the hypothesis that the di↵erence in acquisition costs will translate in a cost saving benefit and/or cost-e↵ectiveness. Relevant articles were identified through systematic review of the literature from the National Center for Biotechnology Pub Med database, ISPOR Digest and clinicaltrials.gov using the following medical subject heading (MESH) terms: Kaposis sarcoma, pegylated liposomal doxorubicin, paclitaxel, AIDS-Related Opportunistic Infections, quality of life, costs, and cost analysis. Based on the results, at present, there is no economic study evaluating the cost-e↵ectiveness of liposomal anthracyclines versus paclitaxel. Available cost-studies also showed that liposomal doxorubicin is more cost e↵ective than liposomal daunorubicin; thus liposomal daunorubicin has been removed from the analysis. Cost analyses were done comparing a full treatment of the two drugs. Cost minimization analysis showed that the treatment with liposomal doxorubicin costs $16, 716 whereas paclitaxel costs $13, 333. After accounting for response rate, the results showed that liposomal doxorubicin costs $36, 339 versus $23, 390 for paclitaxel. Paclitaxel is the dominant intervention due to its lower acquisition cost and higher response rate vs. liposomal doxorubicin. In conclusion, there is a large di↵erence in acquisition cost of liposomal doxorubicin and paclitaxel (paclitaxel being less expensive than liposomal doxorubicin). After accounting for all the factors that contribute to cost and response rate, paclitaxel is less costly and cost-e↵ective when compared to liposomal doxorubicin.
Type Text
Publisher University of Utah
Subject MESH Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Sarcoma, Kaposi; Drug Therapy; Paclitaxel; Doxorubicin; Anthracyclines; Quality of Life; Costs and Cost Analysis; Cost-Benefit Analysis
Dissertation Institution University of Utah
Dissertation Name Master of Science
Language eng
Relation is Version of Digital reproduction of Cost Effectiveness of Liposomal Doxorubicin versus Paclitaxel for the Treatment of Advanced AIDS-Related Kaposis Sarcoma. Spencer S. Eccles Health Sciences Library. Print version available at J. Willard Marriott Library Special Collections.
Rights Management Copyright © Karina Pupio Raimundo 2011
Format application/pdf
Format Medium application/pdf
Format Extent 1,314,839 bytes
Source Original in Marriott Library Special Collections. RC39.5 2011.R34
ARK ark:/87278/s6b313h0
Setname ir_etd
ID 196388
Reference URL https://collections.lib.utah.edu/ark:/87278/s6b313h0
Back to Search Results